Glycomimetic E-selectin Antagonists for Inhibiting Cell Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modulators of selectin-mediated function, such as PSGL-1 protein, fucoidan, glycyrrhizin, and heparin, are unsuitable for drug development due to insufficient activity, toxicity, lack of specificity, and poor ADME characteristics, making it necessary to identify effective inhibitors of E-selectin-mediated cell adhesion for conditions like autoimmune and inflammatory diseases.
Innovation Solution
Development of specific E-selectin antagonists, including glycomimetics with triazole and indole derivatives, which are designed to inhibit E-selectin-mediated functions at nanomolar concentrations, formulated as pharmaceutical compositions for various administration routes, including topical, oral, and intravenous, to treat conditions like autoimmune diseases and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing modulators (PSGL-1 protein, fucoidan, glycyrrhizin, heparin) are used to inhibit selectin-mediated function, then some inhibitory activity is achieved, but they suffer from insufficient activity, toxicity, lack of specificity, and poor ADME characteristics
Solution Approach 1:
The patent modifies the chemical structure of known selectin modulators by changing parameters such as molecular weight, functional groups, and stereochemistry. Specifically, the invention uses glycomimetics with modified sugar moieties and peptide backbones to optimize binding affinity while reducing toxicity. The compounds are designed with specific D-amino acid residues and non-natural sugars to improve stability and reduce immunogenicity.
Solution Approach 2:
The patent creates composite molecules combining carbohydrate moieties with peptide structures (glycomimetics). These hybrid compounds integrate the binding specificity of sugars with the stability and pharmacokinetic properties of peptides. The composite structure includes sialyl-Lewisx mimetics coupled to peptide backbones, providing both high affinity for E-selectin and improved ADME characteristics.
2Reliability
If existing modulators are used, then some inhibition of cell adhesion is achieved, but they lack specificity and have insufficient activity at therapeutic concentrations
Solution Approach 1:
The patent introduces specific local structural features into the modulator molecules to enhance binding specificity. This includes incorporating D-amino acid residues at specific positions in the peptide backbone and using non-natural sugar moieties with specific stereochemistry. These localized modifications create high-affinity interactions with E-selectin while maintaining selectivity against other selectin family members.
Solution Approach 2:
The patent optimizes molecular parameters such as the length and composition of peptide linkers, the configuration of sugar rings, and the positioning of functional groups to maximize binding affinity. The compounds are designed to achieve nanomolar or picomolar affinity constants, representing significant improvements in potency over existing modulators.
3Adaptability or versatility
If existing modulators are developed into drugs, then treatment of inflammatory diseases is possible, but they suffer from poor ADME characteristics and availability of material
Solution Approach 1:
The patent designs compounds with improved pharmacokinetic properties including enhanced metabolic stability and reduced immunogenicity. The use of D-amino acids and non-natural sugars creates molecules that are more resistant to degradation by proteases and less likely to trigger immune responses, thereby improving half-life and availability for therapeutic use.
Solution Approach 2:
The patent modifies physical and chemical parameters of the modulators to improve solubility, permeability, and metabolic stability. The glycomimetic structures are designed with appropriate hydrophilic and hydrophobic regions to optimize bioavailability. The compounds are formulated as pharmaceutical compositions with suitable excipients to enhance delivery and stability in vivo.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The E-selectin antagonists demonstrate significant inhibitory activity, providing therapeutic benefits in conditions associated with excessive selectin activity, such as autoimmune diseases and cancer, by effectively disrupting selectin-mediated cell adhesion without the limitations of existing modulators.
Implementation Method 1
E-selectin binds to the carbohydrate sialyl-Lewisx (SLex), which is presented as a glycoprotein or glycolipid on the surface of certain leukocytes... The compounds are particular E-selectin antagonists... effectively disrupting selectin-mediated cell adhesion
Data Source
AI summary
Compounds, compositions and methods are provided for inhibiting in vitro and in vivo processes mediated by E-selectin binding. More specifically, particular glycomimetic compounds are described, wherein the compounds are E-selectin antagonists.